Analyst consensus rating
TScan Therapeutics Analyst Rating: none
Direct answer
TScan Therapeutics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.00.
Forecast evidence checked September 4, 2026.
Get free TScan Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.37
- Average price target
- $6.00
- High price target
- $7.00
- Low price target
- $5.00
- Low target gap
- +1,248.1%
- Target upside
- +1,517.7%
- High target gap
- +1,787.3%
- Target range width
- 539.2%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- September 4, 2026
- Valid through
- September 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for TScan Therapeutics?
TScan Therapeutics has a verified none consensus. The same dataset has an average price target of $6.00.
How far are TScan Therapeutics's low and high targets from the recorded price?
The low target implies +1,248.1%, while the high target implies +1,787.3%.
How many analysts are included in TScan Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is TScan Therapeutics's target upside or downside calculated?
The average target of $6.00 is divided by the recorded price of $0.37, then one is subtracted to produce +1,517.7%. This does not guarantee a future return.
When was TScan Therapeutics's analyst forecast verified?
The data was verified on 2026-09-04. The dataset is valid through 2026-09-11.